var data={"title":"Prothrombin complex concentrate, 3-factor, unactivated, from human plasma: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Prothrombin complex concentrate, 3-factor, unactivated, from human plasma: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6175?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-patient-drug-information\" class=\"drug drug_patient\">see &quot;Prothrombin complex concentrate, 3-factor, unactivated, from human plasma: Patient drug information&quot;</a> and <a href=\"topic.htm?path=prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Prothrombin complex concentrate, 3-factor, unactivated, from human plasma: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169679\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Bebulin;</li>\n      <li>Profilnine;</li>\n      <li>Profilnine SD</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169690\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antihemophilic Agent;</li>\n      <li>\n        Blood Product Derivative;</li>\n      <li>\n        Prothrombin Complex Concentrate (PCC)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169681\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: Factor IX complex (Human) [Factors II, IX, X] (Bebulin, Profilnine) contains low or nontherapeutic levels of factor VII component</b> and should not be confused with Prothrombin Complex Concentrate (Human) [(Factors II, VII, IX, X), Protein C, Protein S] (Kcentra, Octaplex) which contains therapeutic levels of factor VII.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Control or prevention of bleeding in patients with factor IX deficiency (hemophilia B [Christmas disease]):</b> Dosage is expressed in units of factor IX activity and must be individualized based on severity of factor IX deficiency, extent and location of bleeding, and clinical status of patient. Close laboratory monitoring of the factor IX level is required to determine proper dosage, particularly with severe hemorrhage and major surgery. Larger doses than those derived from the formula below may be required, especially if treatment is delayed. When multiple doses are required, administer at 24-hour intervals unless otherwise specified.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Formula for units required to raise blood level %:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Bebulin: In general, factor IX 1 unit/kg will increase the plasma factor IX level by 0.8%</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Number of Factor IX units required = body weight (kg) x desired factor IX increase (as % of normal) x 1.2 units/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Profilnine: In general, factor IX 1 unit/kg will increase the plasma factor IX level by 1%:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Number of factor IX units required = bodyweight (kg) x desired factor IX increase (as % of normal) x 1 unit/kg</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">For example, to increase factor IX level to 25% of normal in a 70 kg patient: Number of factor IX units needed = 70 kg x 25 x 1 unit/kg = 1,750 units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">\n      <b>As a general rule, the level of factor IX required for treatment of different conditions is listed below: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Hemorrhage:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Minor bleeding (early hemarthrosis, minor epistaxis, gingival bleeding, mild hematuria):</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Bebulin: Raise factor IX level to 20% of normal (typical initial dose: 25 to 35 units/kg); average duration of treatment is 1 day. A single dose is usually sufficient or a second dose may be given after 24 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Profilnine: Raise factor IX level to 20% to 30% of normal (initial dose: 20 to 30 units/kg) every 16 to 24 hours for 1 to 2 days for minor hemorrhage or until hemorrhage stops and healing has been achieved.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Moderate bleeding (severe joint bleeding, early hematoma, major open bleeding, minor trauma, minor hemoptysis, hematemesis, melena, major hematuria):</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Bebulin: Raise factor IX level to 40% of normal (typical initial dose: 50 to 65 units/kg); average duration of treatment is 2 days or until adequate wound healing.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Profilnine: Raise factor IX level to 20% to 30% of normal (initial dose: 20 to 30 units/kg) every 16 to 24 hours for 2 to 7 days for moderate hemorrhage or until hemorrhage stops and healing has been achieved.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Major bleeding (severe hematoma, major trauma, severe hemoptysis, hematemesis, melena):</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Bebulin: Raise factor IX level to &ge;60% of normal (typical initial dose: 75 to 90 units/kg); average duration of treatment is 2 to 3 days or until adequate wound healing.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Profilnine: Raise factor IX level to 30% to 50% of normal (initial dose: 30 to 50 units/kg) every 16 to 24 hours; following this treatment period, maintain factor IX levels at 20% of normal (maintenance dose: 20 units/kg) for 3 to 10 days or until healing has been achieved.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Surgical procedures:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Dental surgery:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Bebulin: Raise factor IX level to 40% to 60% of normal on day of surgery (typical dose: 50 to 75 units/kg). One infusion, administered 1 hour prior to surgery, is generally sufficient for the extraction of one tooth; for the extraction of multiple teeth, replacement therapy may be required for up to 1 week (See dosing guidelines for <i>Minor Surgery</i>).</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Profilnine: Raise factor IX level to 50% of normal immediately prior to procedure; maintain factor IX levels at 30% to 50% of normal (maintenance dose: 30 to 50 units/kg) every 16 to 24 hours for 7 to 10 days following surgery or until healing has been achieved.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Minor surgery:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Bebulin: Raise factor IX level to 40% to 60% of normal on day of surgery (typical initial dose: 50 to 75 units/kg). Decrease factor IX level from 40% to 60% of normal to 20% to 40% of normal during initial postoperative period (1 to 2 weeks or until adequate wound healing) [typical dose: 26 to 65 units/kg]. The preoperative dose should be given 1 hour prior to surgery. The average dosing interval may be every 12 hours initially, then every 24 hours later in the postoperative period.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Profilnine: Raise factor IX level to 30% to 50% of normal (initial dose: 30 to 50 units/kg) prior to surgery (<b>Note:</b> Surgery type not specified by the manufacturer); maintain factor IX levels at 30% to 50% of normal (maintenance dose: 30 to 50 units/kg) every 16 to 24 hours for 7 to 10 days following surgery or until healing is achieved.</p>\n    <p style=\"text-indent:-4em;margin-left:10em;\">\n      <i>Major surgery:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Bebulin: Raise factor IX level to &ge;60% of normal on day of surgery (typical initial dose: 75 to 90 units/kg). Decrease factor IX level from &ge;60% of normal to 20% to 60% of normal during initial postoperative period (1 to 2 weeks) [typical dose: 25 to 75 units/kg]; further decrease to maintain a factor IX level of 20% of normal during late postoperative period (&ge;3 weeks) and continuing until adequate wound healing is achieved [typical dose: 25 to 35 units/kg]. The preoperative dose should be given 1 hour prior to surgery. The average dosing interval may be every 12 hours initially, then every 24 hours later in the postoperative period.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Profilnine: Raise Factor IX level to 30% to 50% of normal (initial dose: 30 to 50 units/kg) prior to surgery (<b>Note:</b> Surgery type not specified by the manufacturer); maintain factor IX levels at 30% to 50% of normal (maintenance dose: 30 to 50 units/kg) every 16 to 24 hours for 7 to 10 days following surgery or until healing is achieved.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Life-threatening hemorrhage associated with warfarin (off-label use):</b> IV: <b>Note:</b> Products contain low or nontherapeutic levels of factor VII component; therefore, additional fresh frozen plasma (FFP) or factor VIIa may be considered (Masotti 2011). When immediate INR reversal is required, concomitant use of 1 to 2 units of FFP should be considered to ensure acute INR reversal (Baker 2004; Holland 2009). Coadminister vitamin K (phytonadione) 5 to 10 mg by slow IV infusion (ACCP [Guyatt 2012]); vitamin K may be repeated every 12 hours if INR is persistently elevated. Factor IX complex (human) dosing has not been established in this setting; the following regimens have been used with some success.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">The following 2 methods have been suggested, but are not product specific:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Adjusted-dose regimen, weight based (Liumbruno 2009):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">INR &lt;2: 20 units/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">INR 2 to 4: 30 units/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">INR &gt;4: 50 units/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> If after administration, INR remains &gt;1.5 consider repeating dose appropriate for INR.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>May also determine dose based on presenting INR and estimated functional prothrombin complex (PC) expressed as percentage of normal plasma levels (see table; Masotti 2011):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Units needed to be infused = (<b>target</b> % of functional PC to be reached &ndash; <b>current</b> estimated % of functional PC) x kg of body weight</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Example:</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patient (weight: 70 kg) presents with INR of 4.5 which corresponds to an <b>estimated % functional PC</b> of 10% (see table). Target INR of 1.4 corresponds to an <b>estimated target % functional PC</b> of 40%.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Units needed to be infused = (40 - 10) x 70 kg = 2,100 units</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Conversion of the INR to Estimated Functional Prothrombin Complex (PC)</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">INR Value</p></th>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Estimated</p>\n            <p style=\"text-indent:0em;\">Functional PC</p></th></tr></thead>\n      <tbody>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;5</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">5%</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">4 to 4.9</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">10%</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">2.6 to 3.2</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">15%</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">2.2 to 2.5</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">20%</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1.9 to 2.1</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">25%</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">1.7 to 1.8</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">30%</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">1.4 to 1.6</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">40%</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">1 to 1.3</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">100%</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Intracranial hemorrhage associated with warfarin (off-label use):</b> IV: <b>Note:</b> Factor IX complex (human) products contain low or nontherapeutic levels of factor VII component (ie, considered a 3-factor PCC). Four-factor PCC is preferred. Administer with vitamin K IV (NCS/SCCM [Frontera 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Fixed-dose regimen, weight based: </i>INR &ge;1.4: 50 units/kg; repeat INR within 15 to 60 minutes and serially every 6 to 8 hours for the next 24 to 48 hours. If INR remains &ge;1.4 within the first 24 to 48 hours after initial dose, use FFP (alone) for further correction. For initial reversal, it is suggested to administer factor IX complex (PCC) alone rather than combined with FFP or recombinant factor VIIa (NCS/SCCM [Frontera 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169686\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Prothrombin complex concentrate, 3-factor, unactivated, from human plasma: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Control or prevention of bleeding in patients with factor IX deficiency (hemophilia B [Christmas disease]) (off-label use):</b> IV: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169682\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15881408\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15881409\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; monitor factor IX levels. Use with caution due to the risk of thromboembolic complications.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169668\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bebulin: 200-1200 units (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Profilnine: 500 units (1 ea); 1000 units (1 ea); 1500 units (1 ea) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Profilnine SD: 500 units (1 ea); 1000 units (1 ea); 1500 units (1 ea) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Profilnine: 500 units (1 ea); 1000 units (1 ea); 1500 units (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169654\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25573582\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Strengths expressed as an approximate value. Consult individual vial labels for exact potency within each vial.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169671\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Solution should be infused at room temperature. Rate should not exceed 2 mL/minute for Bebulin or 10 mL/minute for Profilnine. Vasomotor reactions may result from rapid administration; do not exceed the recommended infusion rates. Slowing the rate of infusion, changing the lot of medication, or administering antihistamines may relieve some adverse reactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169670\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Factor IX deficiency (hemophilia B  [Christmas disease]):</b> Prevention and control of bleeding in patients with factor IX deficiency (hemophilia B or Christmas disease) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Limitations of use: Not indicated for the treatment of other factor deficiencies (eg, factor II, VII, VIII, X), treatment of hemophilia A patients with inhibitors to factor VIII, or treatment of bleeding caused by low levels of liver-dependent coagulation factors.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25725589\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Factor IX deficiency (hemophilia B [Christmas disease]) (children and adolescents); Intracranial hemorrhage associated with warfarin; Life-threatening hemorrhage associated with warfarin</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14634078\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Factor IX Complex may be confused with Factor IX</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Safety concern:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Factor IX Complex may be confused with Factor IX</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">The term &ldquo;Prothrombin Complex Concentrate&rdquo; or &ldquo;PCC&rdquo; has been used to describe both Factor IX Complex (Human) [Factors II, IX, X] and Prothrombin Complex Concentrate (Human) [(Factors II, VII, IX, X), Protein C, Protein S]. <b>Factor IX Complex (Human) [Factors II, IX, X] (Bebulin, Profilnine) contains low or nontherapeutic levels of factor VII component </b>and should not be confused with Prothrombin Complex Concentrate (Human) [(Factors II, VII, IX, X), Protein C, Protein S] (Kcentra, Octaplex) which contains therapeutic levels of factor VII.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169661\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Flushing, thrombosis (sometimes fatal)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills, drowsiness, headache, lethargy, paresthesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Disseminated intravascular coagulation, heparin-induced thrombocytopenia (with products containing heparin)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylactic shock</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Antibody development (to clotting factor)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169674\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Profilnine: There are no contraindications listed in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bebulin: Hypersensitivity reactions to factor IX complex or any component of the formulation; known allergy to heparin; history of heparin-induced thrombocytopenia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169658\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Antibody formation: The development of factor IX antibodies (or inhibitors) has been reported with factor IX therapy (usually occurs within the first 10 to 20 exposure days); the risk of severe hypersensitivity reactions occurring may be greater in these patients. When clinical response is suboptimal, the patient has reached a specified number of exposure days, or patient is to undergo surgical procedure, screen for inhibitors. Patients with severe hemophilia compared to those with mild or moderate hemophilia are more likely to develop inhibitors (WFH [Srivastava 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions: Hypersensitivity and anaphylactic/anaphylactoid reactions have been reported with use. Delayed reactions (up to 20 days after infusion) in previously untreated patients may also occur. Due to potential for allergic reactions, the initial ~10 to 20 administrations should be performed under appropriate medical supervision. Hypersensitivity reactions may be associated with factor IX inhibitor development; patients experiencing allergic reactions should be evaluated for factor IX inhibitors. If severe hypersensitivity reactions occur, consider the use of alternative hemostatic measures (WFH [Srivastava 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thrombotic events: Thrombotic events (eg, deep vein thrombosis, pulmonary embolism, thrombotic strokes) as well as disseminated intravascular coagulation (DIC) have occurred. Monitor closely for signs or symptoms of intravascular coagulation or thrombosis; risk is higher in patients with congenital or acquired coagulation disorders, and with repeated dosing or high doses. Use with caution when administering to patients with liver disease, history of coronary artery disease, pre- or postoperatively, neonates, or patients at risk of thromboembolic phenomena, disseminated intravascular coagulation or patients with signs of fibrinolysis due to the potential risk of thromboembolic complications. Discontinue infusion immediately if signs or symptoms of thrombosis or embolism occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with extreme caution in patients with hepatic impairment due to the risk of thromboembolic complications.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Heparin: Some products may contain heparin. Use with caution in patients with a history of heparin-induced thrombocytopenia (use of Bebulin is contraindicated).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Human plasma: Product of human plasma; may potentially contain infectious agents that could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Latex: Some product packaging may contain natural rubber latex.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: <b>Factor IX Complex (Human) [Factors II, IX, X] (Bebulin, Profilnine) contains low or nontherapeutic levels of factor VII component </b>and should not be confused with Prothrombin complex concentrate (Human) [(Factors II, VII, IX, X), Protein C, Protein S] (Kcentra, Octaplex) which contains therapeutic levels of factor VII. Factor IX Complex (Human) [Factors II, IX, X] (Bebulin, Profilnine) should not be used for the treatment of factor VII deficiency. When treating warfarin-associated hemorrhage (off-label use), administration of additional fresh frozen plasma (FFP) or factor VIIa should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Clinical response: Response to factor IX administration may vary. If bleeding is not controlled with the recommended dose, determine plasma level of factor IX and follow with a sufficient dose to achieve satisfactory clinical response. If plasma levels of factor IX fail to increase as expected or bleeding continues, suspect the presence of an inhibitor; test as appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Immune tolerance induction: Safety and efficacy have not been established in immune tolerance induction with factor IX products. Nephrotic syndrome has occurred following immune tolerance induction in patients with hemophilia B with factor IX inhibitors receiving factor IX products.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299308\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169663\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10085&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminocaproic Acid: May enhance the adverse/toxic effect of Factor IX Complex (Human) [(Factors II, IX, X)]. Specifically, use of this combination may increase the risk of thrombosis.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169665\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7281044\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Factor IX concentrations do not change significantly in pregnant women with coagulation disorders and women with factor IX deficiency may be at increased risk of postpartum hemorrhage. Pregnant women should have clotting factors monitored, particularly at 28 and 34 weeks gestation and prior to invasive procedures. Prophylaxis may be needed if factor IX concentrations are &lt;50 units/mL at term and treatment should continue for 3 to 5 days postpartum depending on route of delivery. Because parvovirus infection may cause hydrops fetalis or fetal death, a recombinant product is preferred if prophylaxis or treatment is needed. The neonate may also be at an increased risk of bleeding following delivery and should be tested for the coagulation disorder (Chi 2012; Kadir 2009; Lee 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169666\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Levels of factor IX; PT, PTT; INR (when used for warfarin reversal); signs and symptoms of hypersensitivity reactions, DIC, thrombosis, especially in patients with liver disease, surgical patients, and patients with known risk factors predisposing to thrombosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169669\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Average normal factor IX levels are 50% to 150%; patients with severe hemophilia B will have factor IX  levels &lt;1%, often undetectable. Moderate forms of the disease have levels of 1% to 5% while some mild cases may have 5% to 49% of normal factor IX. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169657\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Replaces deficient clotting factor including factor X; hemophilia B, or Christmas disease, is an X-linked recessively inherited disorder of blood coagulation characterized by insufficient or abnormal synthesis of the clotting protein factor IX. Factor IX is a vitamin K-dependent coagulation factor which is synthesized in the liver. Factor IX is activated by factor XIa in the intrinsic coagulation pathway. Activated factor IX (IXa), in combination with factor VII:C, activates factor X to Xa, resulting ultimately in the conversion of prothrombin to thrombin and the formation of a fibrin clot. The infusion of exogenous factor IX to replace the deficiency present in hemophilia B temporarily restores hemostasis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169673\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Half-life elimination: IX component: ~19 to 25 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21121619\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Bebulin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200-1200 unit (Price provided is per AHF Unit): $1.24</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Profilnine Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (Price provided is per AHF Unit): $1.57</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (Price provided is per AHF Unit): $1.57</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1500 unit (Price provided is per AHF Unit): $1.57</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Profilnine SD Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (Price provided is per AHF Unit): $1.57</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (Price provided is per AHF Unit): $1.57</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1500 unit (Price provided is per AHF Unit): $1.57</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539858\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Profilnine SD (LK);</li>\n      <li>Prothrombinex-VF (AU, NZ);</li>\n      <li>Prothromplex (CZ, DK, ES, HU, LT, MT, NO);</li>\n      <li>Prothromplex Total NF (PL);</li>\n      <li>Protromplex (AR);</li>\n      <li>TBSF (AU)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15516194\"></a>Baker RI, Coughlin PB, Gallus AS, et al, &ldquo;Warfarin Reversal: Consensus Guidelines, on Behalf of the Australasian Society of Thrombosis and Haemostasis,&rdquo; <i>Med J Aust,</i> 2004, 181(9):492-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-drug-information/abstract-text/15516194/pubmed\" target=\"_blank\" id=\"15516194\">15516194</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bebulin (factor IX complex) [prescribing information]. Westlake Village, CA: Baxter Healthcare; September 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chi C and Kadir RA, &quot;Inherited Bleeding Disorders in Pregnancy,&quot; <i>Best Pract Res Clin Obstet Gynaecol</i>, 2012, 26(1):103-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-drug-information/abstract-text/22101176/pubmed\" target=\"_blank\" id=\"22101176\">22101176</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20514955\"></a>Chong CT, Lew TWK, Kuperan P, et al, &ldquo;Rapid Reversal of Coagulopathy in Warfarin-Related Intracranial Haemorrhages With Prothrombin Complex Concentrates,&rdquo; <i>Anaesth Intensive Care</i>, 2010, 38(3):474-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-drug-information/abstract-text/20514955/pubmed\" target=\"_blank\" id=\"20514955\">20514955</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22556194\"></a>Dowlatshahi D, Butcher KS, Asdaghi N, et al; Canadian PCC Registry (CanPro) Investigators. Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. <i>Stroke</i>. 2012;43(7):1812-1817.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-drug-information/abstract-text/22556194/pubmed\" target=\"_blank\" id=\"22556194\">22556194</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24671832\"></a>Frontera JA, Gordon E, Zach V, Jovine M, Uchino K, Hussain MS, Aledort L. Reversal of coagulopathy using prothrombin complex concentrates is associated with improved outcome compared to fresh frozen plasma in warfarin-associated intracranial hemorrhage. <i>Neurocrit Care</i>. 2014;21(3):397-406.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-drug-information/abstract-text/24671832/pubmed\" target=\"_blank\" id=\"24671832\">24671832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care</i>. 2016;24(1):6-46. doi: 10.1007/s12028-015-0222-x.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-drug-information/abstract-text/26714677/pubmed\" target=\"_blank\" id=\"26714677\">26714677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):7-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-drug-information/abstract-text/22315257/pubmed\" target=\"_blank\" id=\"22315257\">22315257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i>. 2015;17(10):1467-1507. doi: 10.1093/europace/euv309.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-drug-information/abstract-text/26324838/pubmed\" target=\"_blank\" id=\"26324838\">26324838</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hellstern P, Halbmayer WM, K&ouml;hler M, et al, &ldquo;Prothrombin Complex Concentrates: Indications, Contraindications, and Risks: A Task Force Summary,&rdquo; <i>Thromb Res</i>, 1999, 95(4 Suppl 1):3-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-drug-information/abstract-text/10499902/pubmed\" target=\"_blank\" id=\"10499902\">10499902</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hemphill JC 3rd, Greenberg SM, Anderson CS, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2015;46(7):2032-2060. doi: 10.1161/STR.0000000000000069.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-drug-information/abstract-text/26022637/pubmed\" target=\"_blank\" id=\"26022637\">26022637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19210325\"></a>Holland L, Warkentin TE, Refaai M, et al, &ldquo;Suboptimal Effect of a Three-Factor Prothrombin Complex Concentrate (Profilnine-SD) in Correcting Supratherapeutic International Normalized Ratio Due to Warfarin Overdose,&rdquo; <i>Transfusion</i>, 2009, 49(6):1171-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-drug-information/abstract-text/19210325/pubmed\" target=\"_blank\" id=\"19210325\">19210325</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kadir R, Chi C, and Bolton-Maggs P, &quot;Pregnancy and Rare Bleeding Disorders,&quot; <i>Haemophilia</i>, 2009, 15(5):990-1005.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-drug-information/abstract-text/19298378/pubmed\" target=\"_blank\" id=\"19298378\">19298378</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee CA, Chi C, Pavord SR, et al, &quot;The Obstetric and Gynaecological Management of Women With Inherited Bleeding Disorders-Review With Guidelines Produced by a Taskforce of UK Haemophilia Centre Doctors' Organization,&quot; <i>Haemophilia</i>, 2006, 12(4):301-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-drug-information/abstract-text/16834731/pubmed\" target=\"_blank\" id=\"16834731\">16834731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee JW, &ldquo;Von Willebrand Disease, Hemophilia A and B, and Other Factor Deficiencies,&rdquo; <i>Int Anesthesiol Clin</i>, 2004, 42(3):59-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-drug-information/abstract-text/15205640/pubmed\" target=\"_blank\" id=\"15205640\">15205640</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20011645\"></a>Liumbruno G, Bennardello F, Lattanzio A, et al, &ldquo;Recommendations for the Use of Antithrombin Concentrates and Prothrombin Complex Concentrates,&rdquo; <i>Blood Transfus</i>, 2009, 7(4):325-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-drug-information/abstract-text/20011645/pubmed\" target=\"_blank\" id=\"20011645\">20011645</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lusher JM, &ldquo;Thrombogenicity Associated With Factor IX Complex Concentrates,&rdquo; <i>Semin Hematol</i>, 1991, 28(3 Suppl 6):3-5.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Makris M and Watson HG, &ldquo;The Management of Coumarin-Induced Over-Anticoagulation Annotation,&rdquo; <i>Br J Haematol</i>, 2001, 114(2):271-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-drug-information/abstract-text/11529844/pubmed\" target=\"_blank\" id=\"11529844\">11529844</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Makris M, Greaves M, Phillips WS, et al, &ldquo;Emergency Oral Anticoagulant Reversal: The Relative Efficacy of Infusions of Fresh Frozen Plasma and Clotting Factor Concentrate on Correction of the Coagulopathy,&rdquo; <i>Thromb Haemost</i>, 1997, 77(3):477-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-drug-information/abstract-text/9065997/pubmed\" target=\"_blank\" id=\"9065997\">9065997</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21557810\"></a>Masotti L, Di Napoli M, Godoy DA, et al, &ldquo;The Practical Management of Intracerebral Hemorrhage Associated With Oral Anticoagulant Therapy,&rdquo; <i>Int Stroke J</i>, 2011, 6(3):228-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-drug-information/abstract-text/21557810/pubmed\" target=\"_blank\" id=\"21557810\">21557810</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi: 10.1161/CIR.0000000000000029.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-drug-information/abstract-text/24589852/pubmed\" target=\"_blank\" id=\"24589852\">24589852</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Preston FE, Laidlaw ST, Sampson B, et al, &ldquo;Rapid Reversal of Oral Anticoagulation With Warfarin by a Prothrombin Complex Concentrate (Beriplex): Efficacy and Safety in 42 Patients,&rdquo; <i>Br J Haematol</i>, 2002, 116(3):619-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-drug-information/abstract-text/11849221/pubmed\" target=\"_blank\" id=\"11849221\">11849221</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Profilnine (factor IX complex) [prescribing information]. Los Angeles, CA: Grifols Biologicals Inc; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al; for the World Federation of Hemophilia (WFH). Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1-e47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-drug-information/abstract-text/22776238/pubmed\" target=\"_blank\" id=\"22776238\">22776238</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22811449\"></a>Switzer JA, Rocker J, Mohorn P, et al. Clinical experience with three-factor prothrombin complex concentrate to reverse warfarin anticoagulation in intracranial hemorrhage. <i>Stroke</i>. 2012;43(9):2500-2502.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-drug-information/abstract-text/22811449/pubmed\" target=\"_blank\" id=\"22811449\">22811449</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warren O and Simon B. &ldquo;Massive, Fatal, Intracardiac Thrombosis Associated with Prothrombin Complex Concentrate,&rdquo; <i>Ann Emerg Med</i>, 2009, 53(6):758-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-drug-information/abstract-text/19181420/pubmed\" target=\"_blank\" id=\"19181420\">19181420</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yasaka M, Sakata T, Naritomi H, et al, &ldquo;Optimal Dose of Prothrombin Complex Concentrate for Acute Reversal of Oral Anticoagulation,&rdquo; <i>Thromb Res</i>, 2005, 115(6):455-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-drug-information/abstract-text/15792675/pubmed\" target=\"_blank\" id=\"15792675\">15792675</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10085 Version 114.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F169679\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F169690\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F169681\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F169686\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F169682\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15881408\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15881409\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F169668\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F169654\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F25573582\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F169671\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F169670\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25725589\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F14634078\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F169661\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F169674\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F169658\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299308\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F169663\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F169665\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F7281044\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F169666\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F169669\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F169657\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F169673\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F21121619\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539858\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10085|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-patient-drug-information\" class=\"drug drug_patient\">Prothrombin complex concentrate, 3-factor, unactivated, from human plasma: Patient drug information</a></li><li><a href=\"topic.htm?path=prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-pediatric-drug-information\" class=\"drug drug_pediatric\">Prothrombin complex concentrate, 3-factor, unactivated, from human plasma: Pediatric drug information</a></li></ul></div></div>","javascript":null}